Drugs / Briquilimab
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05600907 | Jan 2023 → Nov 2036 expected | chronic granulomatous disease | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT06592768 | Nov 2024 → Aug 2025 | allergic asthma | Jasper Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05903274 | Jun 2023 → Oct 2024 | myelodysplastic syndrome | Jasper Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04429191 | Jul 2020 → Jun 2023 | acute myeloid leukemia, myelodysplastic syndrome | Jasper Therapeutics, Inc. | Completed | Met primary |
| Phase 1/25 trials · 1 met primary | ||||||
| Phase 1/2 | NCT06353971 | Mar 2024 → Jul 2025 | chronic inducible urticaria | Jasper Therapeutics, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT06162728 | Nov 2023 → Oct 2026 expected | chronic idiopathic urticaria | Jasper Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05357482 | May 2022 → Jan 2026 overdue | beta thalassemia, sickle cell disease | National Heart, Lung, and Blood Institute (NHLBI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04784052 | Dec 2021 → Dec 2027 expected | Fanconi anemia | Porteus, Matthew, MD | Recruiting | Met primary |
| Phase 1/2 | NCT02963064 | Mar 2017 → Jul 2025 | severe combined immunodeficiency | Jasper Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 22 trials | ||||||
| Phase 2 | NCT06736262 | Nov 2024 → Aug 2026 overdue | chronic urticaria | Jasper Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05907746 | Nov 2023 → Oct 2025 overdue | GATA2 deficiency with susceptibility to MDS/AML | National Institutes of Health Clinical Center (CC) | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06145282 Background | Dec 2023 → Oct 2025 overdue | sickle cell disease | National Heart, Lung, and Blood Institute (NHLBI) | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 35
| Date | Issuer | Release |
|---|---|---|
| 2026-01-08 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria jaspertherapeutics.com ↗
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points |
| 2025-07-07 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria jaspertherapeutics.com ↗
In addition, BEACON participants who rolled over into the open-label extension study dosing at 180mg Q8W demonstrated robust clinical efficacy with 8 of 11 (73%) participants achieving a complete response at 12 weeks. |
| 2025-06-14 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria jaspertherapeutics.com ↗
Briquilimab (subcutaneous) administration resulted in deep disease control at 180mg, with 12 of 12 participants (100%) enrolled in the cohort achieving a clinical response within the 8-week preliminary analysis period. |
| 2025-03-01 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting jaspertherapeutics.com ↗
Briquilimab continues to be well tolerated in the study and has continued to demonstrate a favorable safety profile, with no additional adverse events (AEs) potentially related to c-Kit blockade observed. |
| 2025-01-08 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria jaspertherapeutics.com ↗
Substantial reductions in UAS7 were reported, with a mean change from baseline at 8 weeks of -26.6 in the 240mg single-dose cohort and multiple dosing regimens at or above 120mg demonstrating UAS7 changes of more than -25 points. |
| 2024-10-24 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting jaspertherapeutics.com ↗
Both the in-vitro data and the non-human primate data generated in these studies provide further support for the pharmacodynamics of briquilimab, particularly its ability to bind c-Kit and drive mast cell depletion with relatively high potency. |
| 2024-10-23 | Jasper Therapeutics, Inc. | Regulatory Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria jaspertherapeutics.com ↗
Additionally, Jasper also announced it has obtained regulatory clearance in the US and in the EU to further expand the BEACON study in CSU by adding a 360mg single-dose cohort (n=4), and that enrollment in this cohort has commenced. |
| 2024-10-14 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria jaspertherapeutics.com ↗
14 of 15 participants (93%) enrolled in both dose cohorts of the study (n=15) achieved a clinical response within the 6-week preliminary analysis period following administration. |
| 2024-09-10 | Jasper Therapeutics, Inc. | Regulatory Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma jaspertherapeutics.com ↗
Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that Health Canada has cleared the Company’s Clinical Trial Application (CTA) for a Phase 1b/2a asthma challenge study evaluating briquilimab in asthma. |
| 2024-06-14 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress jaspertherapeutics.com ↗ |
| 2024-05-30 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 jaspertherapeutics.com ↗
The asthma study demonstrated that a single dose of briquilimab can deplete mast cells in both inflamed and non-inflamed tissue as well as improve lung function in an allergen-induced asthma model. |
| 2024-03-15 | Jasper Therapeutics, Inc. | Results New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia jaspertherapeutics.com ↗
Data from the study show that briquilimab infusion has a promising safety profile and appears to be well tolerated in patients with FA, with all six patients treated achieving full donor engraftment and full blood count recovery. |
| 2024-02-23 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting jaspertherapeutics.com ↗
Results from both studies demonstrated that a single dose of briquilimab protected against anaphylaxis, as measured by significantly higher core body temperatures in animals treated with briquilimab vs. untreated animals. |
| 2024-01-05 | Jasper Therapeutics, Inc. | Regulatory Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones jaspertherapeutics.com ↗
EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively |
| 2023-12-10 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 jaspertherapeutics.com ↗ |
| 2023-11-02 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023 jaspertherapeutics.com ↗
The study being presented demonstrated that a regimen of briquilimab plus Flu/TBI leads to successful engraftment of donor blood stem cell without the associated short and long-term toxicities that accompany busulfan-based regimens commonly used in transplant of donor or gene-corrected |
| 2023-10-09 | Jasper Therapeutics, Inc. | Regulatory Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria jaspertherapeutics.com ↗
today announced that its investigational new drug (IND) application for a Phase 1b/2a repeat dose clinical study of subcutaneous briquilimab in the treatment of CSU has been cleared by the U.S. Food and Drug Administration (FDA). |
| 2023-09-21 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium jaspertherapeutics.com ↗
All three FA patients who underwent conditioning with briquilimab achieved full blood count recovery. |
| 2023-02-17 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR jaspertherapeutics.com ↗
All 12 patients at Stanford receiving briquilimab-based conditioning and donor cell infusion in an outpatient setting were discharged from the hospital the same day, requiring zero days inpatient |
| 2023-02-17 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR jaspertherapeutics.com ↗
In the follow-up data series presented, 100% total donor chimerism was achieved through six months for the first patient and at three months for the second patient. |
| 2023-02-16 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients jaspertherapeutics.com ↗
First two sickle cell disease participants have achieved 100% donor myeloid chimerism through 100 days follow-up |
| 2023-01-13 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR jaspertherapeutics.com ↗
Durable remissions achieved in 8 of the first 12 AML patients treated at one-year follow up |
| 2023-01-04 | Jasper Therapeutics, Inc. | Regulatory Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant jaspertherapeutics.com ↗ |
| 2023-01-03 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia jaspertherapeutics.com ↗
All three sickle cell study participants treated with briquilimab have successfully engrafted with no briquilimab-related severe adverse events observed. |
| 2022-09-26 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting jaspertherapeutics.com ↗
In the data series presented, 100% complete donor chimerism was achieved through six months for the first patient and at one month for the second patient. |
| 2022-09-15 | Jasper Therapeutics, Inc. | Regulatory Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with severe combined immunodeficiency (SCID) undergoing allogeneic hematopoietic stem cell transplant jaspertherapeutics.com ↗ |
| 2022-04-26 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation jaspertherapeutics.com ↗
JSP191 is well tolerated with no treatment-related severe adverse events in 24 patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in Ph1b dose expansion study |
| 2022-03-31 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting jaspertherapeutics.com ↗
Update: Single-Agent Conditioning with Anti-CD117 Antibody JSP191 Shows Donor Engraftment, Naïve Lymphocyte Production, and Clinical Benefit in Patients with Severe Combined Immunodeficiency (SCID) |
| 2022-02-24 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR jaspertherapeutics.com ↗
Furthermore, this regimen achieved engraftment with neutrophil recovery in all 17 of 17 subjects and clearance of MRD in 12 of 15 subjects positive for MRD at screening. |
| 2021-12-08 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting jaspertherapeutics.com ↗
In this study six of nine non-IL2RG patients with prior hematopoietic cell transplant (HCT), dosed in the initial JSP191 dose escalation (0.1, 0.3, 0.6 and 1.0 mg/kg), achieved HSC engraftment, naïve donor T lymphocyte production, and demonstrated clinical improvement. |
| 2021-06-14 | Jasper Therapeutics, Inc. | Regulatory Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant jaspertherapeutics.com ↗
In addition, the FDA granted rare pediatric disease designation to JSP191 as a conditioning treatment for patients with severe combined immunodeficiency (SCID), a life-threatening genetic illness that is typically fatal within two years without hematopoietic cell transplantation. |
| 2021-05-19 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation jaspertherapeutics.com ↗
At 90 days after transplant, measurable residual disease (MRD) as measured by cytogenetics, flow cytometry and next-generation sequencing was negative (undetected) in five patients and reduced in one patient |
| 2021-02-08 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation jaspertherapeutics.com ↗
Data from the first six patients who received a single dose of JSP191 prior to transplantation showed successful engraftment in all six patients. |
| 2020-12-07 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Announces Data from First Transplant-naive Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent in Patients with SCID Undergoing Hematopoietic Cell Transplantation jaspertherapeutics.com ↗
Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced clinical data from its ongoing multicenter Phase 1 clinical trial of JSP191, a first-in-class anti-CD117 monoclonal antibody, in patients with severe combined immune deficiency (SCID). |
| 2019-12-09 | Jasper Therapeutics, Inc. | Results Jasper Therapeutics Announces Upcoming Data Presentation on Lead Program, JSP191, at 61st American Society of Hematology (ASH) Annual Meeting & Exposition jaspertherapeutics.com ↗
We are encouraged by the initial Phase 1 study results of JSP191 in these fragile patients with SCID and plan to expand clinical development of this antibody beyond patients with SCID. |
All press releases naming this drug 56 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | briquilimab | “Briquilimab is a monoclonal antibody inhibiting stem cell factor (SCF) binding to CD117 (c-Kit).” PMID 41785374 ↗ May 2026 |
| Known as | AMG191 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095110 ↗ |
| Known as | JSP191 | “a new antibody drug (briquilimab, JSP191) improves the success of a blood stem cell transplant” NCT05357482 ↗ |
| Known as | JSP191 (Briquilimab) | “JSP191 (Briquilimab)” NCT05903274 ↗ |
| Action | Inhibit | “The binding of JSP191 to CD117 blocks CD117 from binding to Stem Cell Factor on blood forming stem cells.” NCT02963064 ↗1“Stem cell growth factor receptor inhibitor” CHEMBL5095110 ↗ |
| Modality | Monoclonal antibody | “The biological conditioning regimen, JSP191, is an antibody that binds to CD117.” NCT02963064 ↗ |
| Route | Intravenous | “Procedure: single intravenous infusion of JSP191 antibody” NCT02963064 ↗ |
| Target | KIT | “Stem cell growth factor receptor inhibitor” CHEMBL5095110 ↗ |